Back to Search Start Over

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.

Authors :
Zhang Y
Li P
Fang H
Wang G
Zeng X
Source :
Frontiers in immunology [Front Immunol] 2020 Dec 10; Vol. 11, pp. 604915. Date of Electronic Publication: 2020 Dec 10 (Print Publication: 2020).
Publication Year :
2020

Abstract

Chimeric antigen receptor (CAR) therapy has been proved effective in a stream of clinical trials, especially in hematologic malignancies. However, current CAR therapy is highly personalized as cells used are derived from patients themselves, which can be costly, time-consuming, and sometimes fails to achieve optimal therapeutic results due to poor quality/quantity of patient-derived cells. On the contrary, universal CAR therapy, which is based on healthy individuals' cells, circumvents several limitations of current autologous CAR therapy. To achieve the universality of CAR therapy, the allogeneic cell transplantation related issues, such as graft- versus -host disease (GVHD) and host- versus -graft activities (HVGA), must be addressed. In this review, we focus on current progress regarding GVHD and HVGA in the universal CAR therapy, followed by a universal CAR design that may be applied to allogeneic cells and a summary of key clinical trials in this field. This review may provide valuable insights into the future design of universal CAR products.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2020 Zhang, Li, Fang, Wang and Zeng.)

Details

Language :
English
ISSN :
1664-3224
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
33362790
Full Text :
https://doi.org/10.3389/fimmu.2020.604915